T

TOYOIZUMI K.

Last name: TOYOIZUMI K.

2019 (v1)

Publication

Metadata-only

Designing a pathogen-focused study to address the high unmet medical need represented by carbapenem-resistant gram-negative pathogens – the international, multicenter, randomized, open-label, phase 3 credible-cr study

Bassetti M. Ariyasu M. Binkowitz B.

Carbapenem-resistant (CR) Gram-negative infections, including those caused by Enterobacteriaceae and the non-fermenters, represent the greatest unmet need for new effective treatments. The clinical development of new antibiotics for the treatment of CR infections is challenging and should focus on the individual pathogens irrespective of the...

Uploaded on: April 14, 2023
2020 (v1)

Publication

Metadata-only

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

Bassetti M. Echols R. Matsunaga Y.

Background: New antibiotics are needed for the treatment of patients with life-threatening carbapenem-resistant Gram-negative infections. We assessed the efficacy and safety of cefiderocol versus best available therapy in adults with serious carbapenem-resistant Gram-negative infections. Methods: We did a randomised, open-label, multicentre,...

Uploaded on: March 27, 2023